Today on Outsourcing-Pharma.com   Icon improves its position, Kendle slips again Charles River sails through Q3 Contract manufacturing news in brief FDA failure on foreign inspections frightening Quintiles makes Panama purchase

Related Industry News   Apitope vaccine stops MS in its tracks New safety warning delays Novartis diabetes drug Pretender to Avastin throne poised to enter clinical trails Treating cancer as infectious disease yields results

Breaking News on Outsourcing Pharma
Daily  Tuesday 06 November 2007		Forward to a colleague

	Company Profile DPT - The Industry Source for Semi-solids and Liquids. DPT is a contract development and manufacturing organization (CDMO) specializing in semi-solid and liquid dosage forms providing solutions from concept to commercialization. Click here to learn more about our services... Click Here Access Full Stories Icon improves its position, Kendle slips again Icon has improved its financial position significantly during its third quarter, while its smaller US rival Kendle saw its profit slip again, weighed down by charges from a 2006 acquisition... Read Charles River sails through Q3 Charles River Laboratories sailed through its third quarter, with comfortable gains in both revenue and profits... Read Contract manufacturing news in brief Bioserv Corporation, Mikart, Laureate Pharma, Cenexi and Lonza have all recently announced new contract manufacturing news... Read FDA failure on foreign inspections frightening A US government audit has confirmed the Food and Drug Administration's (FDA's) continual lack of inspection of foreign drug manufacturing plants... Read Quintiles makes Panama purchase Quintiles has bought a contract research organisation (CRO) in Central America to extend its reach in this emerging clinical trials region... Read
	All News Headlines for: November | October | September
	Related Industry News Apitope vaccine stops MS in its tracks UK biopharmaceutical firm Apitope has developed a vaccine that could halt multiple sclerosis in its relentless march to destroy nerve cells... Read New safety warning delays Novartis diabetes drug Swiss firm Novartis today announced that it has contacted regulators regarding the safety of the 100mg dose of its recently approved Type II diabetes drug, Galvus (vildagliptin)... Read Pretender to Avastin throne poised to enter clinical trails BioInvent and ThromboGenics' new anticancer antibody is poised to enter clinical trials and could prove a serious rival to VEGF-blocking drugs, due to fewer side-effects and less drug resistance... Read Treating cancer as infectious disease yields results For the first time, scientists have found a way to target viral antigens deep inside a cancer tumour, and the result is a new therapy that could treat or even prevent the disease... Read Weekly Comment Big pharma lends a helping hand Despite often attracting a barrage of negative publicity, particularly in regard to a perception of putting profits before people, big pharma firms are still capable of showing their human side in times of crisis. Read Previous Headlines EU considers Afghan poppy pilot A proposed pilot programme to divert Afghanistan's infamous and illegal opium supply for legal use in analgesics has been backed by the European Parliament but is facing fierce criticism elsewhere... Read Japan's Tamiflu supply halved Japan will only be receiving 50 per cent of its usual supply of the blockbuster flu drug Tamiflu (oseltamivir) this year, thanks to significantly reduced demand following reports of suicidal behaviour in adolescents... Read Sigma-Aldrich halves miRNA preparation times Sigma-Aldrich has continued its push into the RNAi field with the launch of its new mirPremier miRNA (microRNA) isolation kit that promises to speed up miRNA preparation while removing all large, unwanted RNA... Read Clinical contract news in brief Outsourcing-Pharma.com compiles the news that featured in the clinical contract community this past week, involving PPD, Novotech and Generex... Read GSK blocks new patent rules Just a day before they were due to come into force, GlaxoSmithKline has won a court case to block controversial changes to patent rules... Read Technical / White Papers, Case studies, Web casts Benefits of integrating human tissue research in drug discovery - Technical / White Paper Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analytical testing, QC Bulk ingredients Contract sales & marketing Data management Drug delivery, formulation Fill & finish, packaging Phase I-II Phase III-IV Preclinical Product & Supplier News - Contract Manufacturing Regulatory affairs Supply chain, logistics Validation services

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com